FDA’s Crawford gets strong four-month review
Executive SummaryActing FDA Commissioner Lester Crawford "is doing an awesome job," HHS Secretary Tommy Thompson tells medical device association AdvaMed June 20. "He is out there to make changes. He is already making more changes in the short couple [of] months he's been here...realigning, reorganizing, putting in the risk assessment system....Whether or not he's going to get to be the commissioner, I can't tell you. That's a decision for the President. But I can assure you, until the final commissioner is appointed by the President, this man is in charge"...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.